WO2014151110A1 - Algal oil compositions - Google Patents

Algal oil compositions Download PDF

Info

Publication number
WO2014151110A1
WO2014151110A1 PCT/US2014/025007 US2014025007W WO2014151110A1 WO 2014151110 A1 WO2014151110 A1 WO 2014151110A1 US 2014025007 W US2014025007 W US 2014025007W WO 2014151110 A1 WO2014151110 A1 WO 2014151110A1
Authority
WO
WIPO (PCT)
Prior art keywords
approximately
algal
total
algal oil
composition
Prior art date
Application number
PCT/US2014/025007
Other languages
French (fr)
Inventor
Jeffrey Gerard HIPPLER
Michelle L. COLLINS
Andrew Thompson
Original Assignee
Aurora Algae, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurora Algae, Inc. filed Critical Aurora Algae, Inc.
Priority to CA2905846A priority Critical patent/CA2905846A1/en
Priority to CN201480015962.2A priority patent/CN105102598A/en
Priority to EP14769076.2A priority patent/EP2970817A1/en
Publication of WO2014151110A1 publication Critical patent/WO2014151110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • A23L17/60—Edible seaweed
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/16—Fatty acid esters
    • A21D2/165—Triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A23L2/04—Extraction of juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B3/00—Refining fats or fatty oils
    • C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
    • C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/08—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/187—Eicosapentaenoic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1876—Long-chain fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/202—Algae extracts

Definitions

  • Patent Application Serial No. 14/025,740 filed on September 12, 2013 concurrently with the present application and titled "Conversion of Free Fatty Acids to Ethyl Esters,” which is hereby incorporated by reference.
  • Patent Application Serial No. 14/025,772 filed on September 12, 2013 concurrently with the present application and titled "Compositions and Methods for Utilization of Algal Compounds/' which is hereby incorporated by reference.
  • This invention relates to algal biochemistry, and more specifically, to total algal oil compositions.
  • exemplary total algal oil compositions comprising by total weight between approximately 0% and 99% EPA, and one or more of the following: between approximately 0% and 99% POA, less than approximately 20% saturated fats (including 0% saturated fats or substantially saturated fat free), between approximately 0% and 99% ARA, and/or between approximately 0% and 99% DHA.
  • the saturated fats may comprise PA.
  • exemplary total algal oil compositions comprising by total weight at least 20% EPA and one or more of the following: at least 17% POA, at least 13% PA, less than approximately 10% ARA, and/or substantially no DHA.
  • Additional exemplary total algal oil compositions may comprise by total weight at least approximately 30% EPA and one or more of the following: at least approximately 27% POA, at least approximately 23% PA, less than approximately 10% ARA, and/or substantially no DHA.
  • the exemplary total algal oil compositions provided herein may be processed from a whole algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash. According to some exemplary algal biomass
  • the algal biomass is produced by algal genus Nannochloropsis.
  • Further exemplary total algal oil compositions may be in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacylglycerol (SQDG).
  • EE ethyl ester
  • MAG mono, di- or triacylglycerol
  • PL phospholipid
  • GL galactolipid
  • FFA free fatty acid
  • SQLDG sulfoquinovosyl diacylglycerol
  • FIG. 1 is a table of actual data for an exemplary whole biomass
  • WB fatty acid methyl ester
  • Crude exemplary crude biomass
  • TAO total algal oil composition
  • FIG. 2 shows an actual fatty acid (in ethyl ester form) profile for an exemplary total algal oil composition that was produced and analyzed by the present inventors.
  • a fatty acid is a carboxylic acid with a long aliphatic tail (chain), which is either saturated or unsaturated. Most naturally occurring fatty acids have a chain of an even number of carbon atoms, from 4 to 28. Saturated fatty acids have no double bonds between carbon atoms. Unsaturated fatty acids have one or more double bonds between carbon atoms. When counting from the terminal methyl carbon toward the carbonyl carbon on an unsaturated fatty acid, the first double bond signifies the omega double bond, such as observed in omega 3, omega 6, or omega 7 fatty acids.
  • Palmitoleic acid is an omega-7 monounsaturated fatty acid with a 16-carbon chain with one double bond, denoted as C16:l n7.
  • a beneficial fatty acid it has been shown to suppress inflammation.
  • Dietary sources of omega-7 are found in animal and plant sources, including sea buckthorn berries, macadamia nuts, cold water fish and dairy fat. These sources, however, are not concentrated and/or purified sources of POA and often contain a mixed fatty acid profile of saturated and polyunsaturated fats.
  • Palmitic acid is a saturated fatty acid with a 16-carbon chain and no double bonds, denoted as C16:0. Consumption of saturated fats such as palmitic acid is believed to increase the risk of developing diabetes, obesity, stroke and cardiovascular diseases.
  • Alpha linolenic acid is an omega-3 polyunsaturated fatty acid (PUFA) with an 18-carbon chain and three cis double bonds. The first double bond is located at the third carbon from the methyl end of the fatty acid chain, denoted as C18:3 n3.
  • PUFA polyunsaturated fatty acid
  • Arachidonic acid is an omega-6 PUFA with a 20-carbon chain and four cis-double bonds; the first double bond is located at the sixth carbon from the omega end.
  • ARA is also denoted as C20:4 n6.
  • Examples of dietary sources of omega-6 PUFAs include refined vegetable oils, such as corn and soy oil, seeds and nuts and the oils extracted from them. Consumption is therefore sufficient in the average diet.
  • Eicosapentaenoic acid is an omega-3 fatty acid PUFA with the following connotation C20:5 n3. It is a carboxylic acid with a 20-carbon chain and five cis double bonds; the first double bond is located at the third carbon from the omega end.
  • Docosahexaenoic acid is an omega-3 fatty acid PUFA. It is a carboxylic acid with a 22-carbon chain and six cis double bonds; the first double bond is located at the third carbon from the omega end. DHA is also denoted as C22:6 n3.
  • exemplary total algal oil compositions comprising by total weight between approximately 0% and 99% EPA, and one or more of the following: between approximately 0% and 99% POA, less than approximately 20% saturated fats (including 0% saturated fats or substantially saturated fat free), between approximately 0% and 99% ARA, and/or between approximately 0% and 99% DHA.
  • the saturated fats may comprise PA.
  • exemplary total algal oil compositions comprising by total weight at least 20% EPA and one or more of the following: at least 17% POA, at least 13% PA, less than approximately 10% ARA, and/or substantially no DHA.
  • Additional exemplary total algal oil compositions may comprise by total weight at least approximately 30% EPA and one or more of the following: at least approximately 27% POA, at least approximately 23% PA, less than approximately 10% ARA, and/or substantially no DHA.
  • compositions herein may comprise a range (for example, approximately 0% to 99%) of saturated fats.
  • the exemplary total algal oil compositions provided herein may be processed from a whole algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash. According to some exemplary algal biomass
  • the algal biomass is produced by algal genus Nannochloropsis.
  • Further exemplary total algal oil compositions may be in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacylglycerol (SQDG).
  • EE ethyl ester
  • MAG mono, di- or triacylglycerol
  • PL phospholipid
  • GL galactolipid
  • FFA free fatty acid
  • SQLDG sulfoquinovosyl diacylglycerol
  • FIG. 1 is a table of actual data for an exemplary whole biomass
  • WB in a form of a fatty acid methyl ester
  • Crude in a form of a fatty acid methyl ester
  • TAO total algal oil composition
  • the exemplary total algal oil compositions provided herein may be processed from a whole algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash.
  • the processing of the whole algal biomass results in a crude biomass.
  • crude algal oil may be converted to free fatty acids in an aqueous system.
  • the crude algal oil is typically a mixture of oils, waxes, chlorophyll, and other species that originally supported the functioning of the algae plant.
  • the free fatty acids may be extracted from other algal impurities.
  • the free fatty acids may be mixed with a mineral acid and an alcohol to impart a phase separation of the mixture.
  • An esterification reaction may occur to convert the free fatty acids to the ethyl ester form.
  • the ethyl esters may then be isolated from the mixture.
  • various algae species may be the source of the whole algal biomass and crude algal oil from which the free fatty acids may be obtained.
  • Algae are mostly aquatic photosynthetic organisms that range from microscopic flagellate to giant kelp. Algae may be loosely grouped into seven categories: Euglenophyta (euglenoids), Chrysophyta (golden-brown algae), Pyrrophyta (fire algae), Dinoflagellata, Chlorophyta (green algae), Rhodophyta (red algae), Paeophyta (brown algae), and Xanthophyta (yellow- green algae). Lipid extracted from any algae genus may be used in the various embodiments of the present invention, including Amphora, Anabaena,
  • Cyclotella Cylindrotheca, Dunaliella, Emiliania, Euglena, Glossomastix,
  • Haematococcus Isochrysis, Monochrysis, Monoraphidium, Nannochloris, Nannochloropsis, Navicula, Nephrochloris, Nephroselmis, Nitzschia, Nodularia, Nostoc, Oochromonas, Oocystis, Oscillatoria, Pavlova, Phaeodactylum,
  • FIG. 2 shows an actual fatty acid (in ethyl ester form) profile for an exemplary total algal oil composition that was produced and analyzed by the present inventors. As illustrated by FIG. 2, exemplary total algal oil
  • compositions may comprise by total weight at least 30% EPA, at least
  • exemplary total algal oil compositions may comprise by total weight at least approximately 20% EPA and one or more of at least approximately 17% POA, at least approximately 13% PA, less than approximately 10% ARA, and substantially no DHA.
  • the various algal oil compositions provided herein may further be in ethyl ester form.
  • ethyl esters are derived by reacting free fatty acids with ethanol. Called esterification, the resulting ethyl ester allows for the fractional distillation (concentration) of the long chain fatty acids at lower temperatures. This step allows for the selective concentration of the fatty acids to levels greater than found in nature.
  • the ethyl ester forms of the various exemplary algal oil compositions provided herein may be converted to a triglyceride form by performing an enzymatic reaction with the ethyl ester form in the presence of glycerol, heating under a vacuum, and filtering out the enzymes.
  • immobilized lipase enzymes such as that isolated from Candida antarctica and/or commercially sold by Novozyme or Sigma Aldrich may be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided herein are exemplary total algal oil compositions comprising by total weight between approximately 0% and 99% EPA, and one or more of the following: between approximately 0% and 99% POA, less than approximately 20% saturated fats (including 0% saturated fats or substantially saturated fat free), between approximately 0% and 99% ARA, and/or between approximately 0% and 99% DHA. According to further exemplary total algal oil compositions, the saturated fats may comprise PA. Also provided herein are exemplary total algal oil compositions comprising by total weight at least 20% EPA and one or more of the following: at least 17% POA, approximately 0% to 20% saturated fats, less than approximately 10% ARA, and/or substantially no DHA.

Description

ALGAL OIL COMPOSITIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] The present application claims the benefit and priority of U.S.
Provisional Patent Application Serial No. 61/800,114 filed on March 15, 2013 and titled "(EPA) Algal Biomass and Oil Compositions and Impact on Health/' which is hereby incorporated by reference.
[002] The present application claims the benefit and priority of U.S.
Provisional Patent Application Serial No. 61/800,029 filed on March 15, 2013 and titled "Microalga Species and Industrial Applications/' which is hereby incorporated by reference.
[003] The present application is related to U.S. Non-Provisional
Patent Application Serial No. 14/025,766 filed on September 12, 2013 concurrently with the present application and titled "Algal Omega 7 Compositions," which is hereby incorporated by reference.
[004] The present application is related to U.S. Non-Provisional
Patent Application Serial No. 14/025,740 filed on September 12, 2013 concurrently with the present application and titled "Conversion of Free Fatty Acids to Ethyl Esters," which is hereby incorporated by reference.
[005] The present application is related to U.S. Non-Provisional
Patent Application Serial No. 14/025,756 filed on September 12, 2013 concurrently with the present application and titled "Algal Omega 7 and Algal Omega 3 Blend Compositions," which is hereby incorporated by reference.
[006] The present application is related to U.S. Non-Provisional
Patent Application Serial No. 14/025,772 filed on September 12, 2013 concurrently with the present application and titled "Compositions and Methods for Utilization of Algal Compounds/' which is hereby incorporated by reference.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[007] This invention relates to algal biochemistry, and more specifically, to total algal oil compositions.
SUMMARY OF THE INVENTION
[008] Provided herein are exemplary total algal oil compositions comprising by total weight between approximately 0% and 99% EPA, and one or more of the following: between approximately 0% and 99% POA, less than approximately 20% saturated fats (including 0% saturated fats or substantially saturated fat free), between approximately 0% and 99% ARA, and/or between approximately 0% and 99% DHA. According to further exemplary total algal oil compositions, the saturated fats may comprise PA.
[009] Also provided herein are exemplary total algal oil compositions comprising by total weight at least 20% EPA and one or more of the following: at least 17% POA, at least 13% PA, less than approximately 10% ARA, and/or substantially no DHA.
[0010] Additional exemplary total algal oil compositions may comprise by total weight at least approximately 30% EPA and one or more of the following: at least approximately 27% POA, at least approximately 23% PA, less than approximately 10% ARA, and/or substantially no DHA.
[0011] The exemplary total algal oil compositions provided herein may be processed from a whole algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash. According to some exemplary algal biomass
compositions, the algal biomass is produced by algal genus Nannochloropsis.
[0012] Further exemplary total algal oil compositions may be in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacylglycerol (SQDG).
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a table of actual data for an exemplary whole biomass
("WB") (in a form of a fatty acid methyl ester (FAME)), an exemplary crude biomass ("Crude") (in a form of a FAME), and an exemplary total algal oil composition ("TAO") (in ethyl ester form).
[0014] FIG. 2 shows an actual fatty acid (in ethyl ester form) profile for an exemplary total algal oil composition that was produced and analyzed by the present inventors.
DETAILED DESCRIPTION OF THE INVENTION
[0015] A fatty acid is a carboxylic acid with a long aliphatic tail (chain), which is either saturated or unsaturated. Most naturally occurring fatty acids have a chain of an even number of carbon atoms, from 4 to 28. Saturated fatty acids have no double bonds between carbon atoms. Unsaturated fatty acids have one or more double bonds between carbon atoms. When counting from the terminal methyl carbon toward the carbonyl carbon on an unsaturated fatty acid, the first double bond signifies the omega double bond, such as observed in omega 3, omega 6, or omega 7 fatty acids.
[0016] Palmitoleic acid (POA) is an omega-7 monounsaturated fatty acid with a 16-carbon chain with one double bond, denoted as C16:l n7. A beneficial fatty acid, it has been shown to suppress inflammation. Dietary sources of omega-7 are found in animal and plant sources, including sea buckthorn berries, macadamia nuts, cold water fish and dairy fat. These sources, however, are not concentrated and/or purified sources of POA and often contain a mixed fatty acid profile of saturated and polyunsaturated fats.
[0017] Palmitic acid (PA) is a saturated fatty acid with a 16-carbon chain and no double bonds, denoted as C16:0. Consumption of saturated fats such as palmitic acid is believed to increase the risk of developing diabetes, obesity, stroke and cardiovascular diseases.
[0018] Alpha linolenic acid (ALA) is an omega-3 polyunsaturated fatty acid (PUFA) with an 18-carbon chain and three cis double bonds. The first double bond is located at the third carbon from the methyl end of the fatty acid chain, denoted as C18:3 n3.
[0019] Arachidonic acid (ARA) is an omega-6 PUFA with a 20-carbon chain and four cis-double bonds; the first double bond is located at the sixth carbon from the omega end. ARA is also denoted as C20:4 n6. Examples of dietary sources of omega-6 PUFAs include refined vegetable oils, such as corn and soy oil, seeds and nuts and the oils extracted from them. Consumption is therefore sufficient in the average diet.
[0020] Eicosapentaenoic acid (EPA) is an omega-3 fatty acid PUFA with the following connotation C20:5 n3. It is a carboxylic acid with a 20-carbon chain and five cis double bonds; the first double bond is located at the third carbon from the omega end.
[0021] Docosahexaenoic acid (DHA) is an omega-3 fatty acid PUFA. It is a carboxylic acid with a 22-carbon chain and six cis double bonds; the first double bond is located at the third carbon from the omega end. DHA is also denoted as C22:6 n3.
[0022] Provided herein are exemplary total algal oil compositions comprising by total weight between approximately 0% and 99% EPA, and one or more of the following: between approximately 0% and 99% POA, less than approximately 20% saturated fats (including 0% saturated fats or substantially saturated fat free), between approximately 0% and 99% ARA, and/or between approximately 0% and 99% DHA. According to further exemplary total algal oil compositions, the saturated fats may comprise PA.
[0023] Also provided herein are exemplary total algal oil compositions comprising by total weight at least 20% EPA and one or more of the following: at least 17% POA, at least 13% PA, less than approximately 10% ARA, and/or substantially no DHA.
[0024] Additional exemplary total algal oil compositions may comprise by total weight at least approximately 30% EPA and one or more of the following: at least approximately 27% POA, at least approximately 23% PA, less than approximately 10% ARA, and/or substantially no DHA.
[0025] Some or all of the exemplary compositions herein may comprise a range (for example, approximately 0% to 99%) of saturated fats.
[0026] The exemplary total algal oil compositions provided herein may be processed from a whole algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash. According to some exemplary algal biomass
compositions, the algal biomass is produced by algal genus Nannochloropsis.
[0027] Further exemplary total algal oil compositions may be in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacylglycerol (SQDG).
[0028] FIG. 1 is a table of actual data for an exemplary whole biomass
("WB") (in a form of a fatty acid methyl ester), an exemplary crude biomass ("Crude") (in a form of a fatty acid methyl ester), and an exemplary total algal oil composition ("TAO") (in ethyl ester form). The data is reflected in milligrams of subject component per total grams of mass.
[0029] The exemplary total algal oil compositions provided herein may be processed from a whole algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash. The processing of the whole algal biomass results in a crude biomass. [0030] For example, crude algal oil may be converted to free fatty acids in an aqueous system. The crude algal oil is typically a mixture of oils, waxes, chlorophyll, and other species that originally supported the functioning of the algae plant. The free fatty acids may be extracted from other algal impurities. The free fatty acids may be mixed with a mineral acid and an alcohol to impart a phase separation of the mixture. An esterification reaction may occur to convert the free fatty acids to the ethyl ester form. The ethyl esters may then be isolated from the mixture.
[0031] In various embodiments, various algae species may be the source of the whole algal biomass and crude algal oil from which the free fatty acids may be obtained. Algae are mostly aquatic photosynthetic organisms that range from microscopic flagellate to giant kelp. Algae may be loosely grouped into seven categories: Euglenophyta (euglenoids), Chrysophyta (golden-brown algae), Pyrrophyta (fire algae), Dinoflagellata, Chlorophyta (green algae), Rhodophyta (red algae), Paeophyta (brown algae), and Xanthophyta (yellow- green algae). Lipid extracted from any algae genus may be used in the various embodiments of the present invention, including Amphora, Anabaena,
Anikstrodesmis, Botryococcus, Chaetoceros, Chlorella, Chlorococcum,
Cyclotella, Cylindrotheca, Dunaliella, Emiliania, Euglena, Glossomastix,
Haematococcus, Isochrysis, Monochrysis, Monoraphidium, Nannochloris, Nannochloropsis, Navicula, Nephrochloris, Nephroselmis, Nitzschia, Nodularia, Nostoc, Oochromonas, Oocystis, Oscillatoria, Pavlova, Phaeodactylum,
Picochloris, Platymonas, Pleurochrysis, Porphyra, Pseudoanabaena,
Pyramimonas, Scenedesmus, Stichococcus, Synechococcus, Synechocystis, Tetraselmis, Thalassiosira, and Trichodesmium.
[0032] FIG. 2 shows an actual fatty acid (in ethyl ester form) profile for an exemplary total algal oil composition that was produced and analyzed by the present inventors. As illustrated by FIG. 2, exemplary total algal oil
compositions may comprise by total weight at least 30% EPA, at least
approximately 27% palmitoleic acid, at least approximately 23% palmitic acid, less than approximately 10% ARA, and substantially no DHA. Other exemplary total algal oil compositions may comprise by total weight at least approximately 20% EPA and one or more of at least approximately 17% POA, at least approximately 13% PA, less than approximately 10% ARA, and substantially no DHA.
[0033] Additionally, the various algal oil compositions provided herein may further be in ethyl ester form. Such ethyl esters are derived by reacting free fatty acids with ethanol. Called esterification, the resulting ethyl ester allows for the fractional distillation (concentration) of the long chain fatty acids at lower temperatures. This step allows for the selective concentration of the fatty acids to levels greater than found in nature.
[0034] The ethyl ester forms of the various exemplary algal oil compositions provided herein may be converted to a triglyceride form by performing an enzymatic reaction with the ethyl ester form in the presence of glycerol, heating under a vacuum, and filtering out the enzymes. Per some exemplary methods, immobilized lipase enzymes such as that isolated from Candida antarctica and/or commercially sold by Novozyme or Sigma Aldrich may be used.
[0035] While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of a preferred embodiment should not be limited by any of the above-described exemplary embodiments.

Claims

CLAIMS What is claimed is:
1. A total algal oil composition comprising by total weight at least 20% EPA, at least 17% POA, approximately 0% to 20% saturated fats, less than approximately 10% ARA, and substantially no DHA.
2. A total algal oil composition comprising by total weight at least approximately 20% EPA.
3. The total algal oil composition of claim 2, further comprising by total weight at least approximately 17% POA.
4. The total algal oil composition of claim 2, further comprising at least approximately 0% to 20% saturated fats.
5. The total algal oil composition of claim 2, further comprising less than approximately 10% ARA.
6. The total algal oil composition of claim 2, further comprising substantially no DHA.
7. The total algal oil composition of claim 2, further comprising substantially no algal saturated fats.
8. A total algal oil composition comprising by total weight at least approximately 30% EPA, at least approximately 27% POA, 0% to 20% saturated fats, less than approximately 10% ARA, and substantially no DHA.
9. A total algal oil composition comprising by total weight at least approximately 30% EPA, at least approximately 27% POA, and 0% to 20% saturated fats.
10. The total algal oil composition of claim 9, further comprising less than approximately 10% ARA.
11. The total algal oil composition of claim 10, further comprising substantially no DHA.
12. The total algal oil composition of claim 1, as processed from an algal biomass composition comprising approximately 10% lipids, at least approximately 15% carbohydrates, a at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash.
13. The total algal oil composition of claim 8, as processed from an algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash.
14. The total algal oil composition of claim 9, as processed from an algal biomass composition comprising at least approximately 10% lipids, at least approximately 15% carbohydrates, at least approximately 25% protein, at least approximately 3% moisture and at least approximately 5% ash.
15. The algal biomass of claim 12 as produced by algae.
16. The algal biomass of claim 13 as produced by algae.
17. The algal biomass of claim 14 as produced by algae.
18. The algal biomass of claim 15 as produced by algae genus Nannochloropsis.
19. The algal biomass of claim 16 as produced by algal genus Nannochloropsis.
20. The algal biomass of claim 17 as produced by algal genus Nannochloropsis.
21. The total algal fatty acid composition of claim 1, wherein the composition is in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacyl glycerol (SQDG).
22. The total algal fatty acid composition of claim 8, wherein the composition is in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacyl glycerol (SQDG).
23. The total algal fatty acid composition of claim 9, wherein the composition is in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty acid (FFA), or a sulfoquinovosyl diacyl glycerol (SQDG).
PCT/US2014/025007 2013-03-15 2014-03-12 Algal oil compositions WO2014151110A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2905846A CA2905846A1 (en) 2013-03-15 2014-03-12 Algal oil compositions
CN201480015962.2A CN105102598A (en) 2013-03-15 2014-03-12 Algal oil compositions
EP14769076.2A EP2970817A1 (en) 2013-03-15 2014-03-12 Algal oil compositions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361800114P 2013-03-15 2013-03-15
US201361800029P 2013-03-15 2013-03-15
US61/800,114 2013-03-15
US61/800,029 2013-03-15
US14/025,762 2013-09-12
US14/025,762 US20140275483A1 (en) 2013-03-15 2013-09-12 Algal oil compositions

Publications (1)

Publication Number Publication Date
WO2014151110A1 true WO2014151110A1 (en) 2014-09-25

Family

ID=51527995

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2014/025012 WO2014151113A1 (en) 2013-03-15 2014-03-12 Compositions and methods for utilization of algal compounds
PCT/US2014/025019 WO2014151116A1 (en) 2013-03-15 2014-03-12 Conversion of free fatty acids to ethyl esters
PCT/US2014/025007 WO2014151110A1 (en) 2013-03-15 2014-03-12 Algal oil compositions
PCT/US2014/031127 WO2014146133A2 (en) 2013-03-15 2014-03-18 Chlorophyll deficient algal cell with improved growth and production

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2014/025012 WO2014151113A1 (en) 2013-03-15 2014-03-12 Compositions and methods for utilization of algal compounds
PCT/US2014/025019 WO2014151116A1 (en) 2013-03-15 2014-03-12 Conversion of free fatty acids to ethyl esters

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/031127 WO2014146133A2 (en) 2013-03-15 2014-03-18 Chlorophyll deficient algal cell with improved growth and production

Country Status (9)

Country Link
US (6) US20140275483A1 (en)
EP (2) EP2970817A1 (en)
CN (4) CN105102598A (en)
AU (1) AU2014232150A1 (en)
CA (2) CA2905846A1 (en)
HK (1) HK1220683A1 (en)
IL (1) IL240339A0 (en)
MX (1) MX2015012321A (en)
WO (4) WO2014151113A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445619B2 (en) 2013-03-15 2016-09-20 Aurora Algae, Inc. Compositions and methods for utilization of algal compounds

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101942B2 (en) 2009-06-16 2015-08-11 Aurora Algae, Inc. Clarification of suspensions
PT3401388T (en) 2012-12-06 2019-08-29 Synthetic Genomics Inc Algal mutants having a locked-in high light acclimated phenotype
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9266973B2 (en) 2013-03-15 2016-02-23 Aurora Algae, Inc. Systems and methods for utilizing and recovering chitosan to process biological material
US9919016B2 (en) * 2015-02-10 2018-03-20 Bilal Qizilbash Product and method of deploying kale derivatives for anti-cancer effects
CN107287252B (en) 2016-04-01 2020-07-10 中国科学院青岛生物能源与过程研究所 Omega-7 fatty acid composition, method for culturing chrysophyceae to produce composition and application
US11446348B2 (en) 2017-12-30 2022-09-20 Bilal Qizilbash Vegetable powders, methods for manufacturing vegetable powders, and kits thereof
CA3122119A1 (en) * 2018-12-06 2020-06-11 James Cook University Novel composition
WO2021077027A1 (en) * 2019-10-17 2021-04-22 The Regents Of The University Of California Biologically-derived fatty acids and polymers
IL293602A (en) * 2019-12-05 2022-08-01 Vaxa Tech Ltd Nutritional supplement for animal and aquaculture diet and method of making same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091524A1 (en) * 2001-03-22 2004-05-13 Nobukazu Tanaka Stable astaxanthin-containing powdery compositions and process for producing the same
US20100069492A1 (en) * 2006-07-05 2010-03-18 Photonz Corporation Limited Production of ultrapure epa and polar lipids from largely heterotrophic culture

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1271516A (en) * 1968-08-30 1972-04-19 British Petroleum Co Method of separating carboxylic acids or esters thereof
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
WO1994024984A2 (en) * 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
US6541519B2 (en) * 2000-04-06 2003-04-01 Coastside Bio Resources Methods and compositions for treating lipoxygenase-mediated disease states
US7119117B2 (en) * 2001-08-21 2006-10-10 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
US20090181438A1 (en) * 2007-12-04 2009-07-16 The Ohio State University Research Foundation Optimization of biofuel production
US20090311367A1 (en) 2008-06-17 2009-12-17 Perry Stephen C Dietary Supplement
US8367392B2 (en) * 2008-09-05 2013-02-05 Transalgae Ltd. Genetic transformation of algal and cyanobacteria cells by microporation
WO2010027505A2 (en) * 2008-09-05 2010-03-11 Doron Eisenstadt Decreasing rubisco content of algae and cyanobacteria cultivated in high carbon dioxide
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
US9187778B2 (en) 2009-05-04 2015-11-17 Aurora Algae, Inc. Efficient light harvesting
US20110072713A1 (en) * 2009-09-30 2011-03-31 Daniel Fleischer Processing Lipids
WO2011097276A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating arthritis with docosahexaenoic acid
US8152870B2 (en) * 2010-04-06 2012-04-10 Heliae Development, Llc Methods of and systems for producing biofuels
US8603094B2 (en) * 2010-07-26 2013-12-10 Spinal Usa, Inc. Minimally invasive surgical tower access devices and related methods
US9458477B2 (en) * 2010-10-21 2016-10-04 Basf Plant Science Company Gmbh Fatty acid desaturases, elongases, elongation components and uses thereof
EP2673371A1 (en) 2011-02-11 2013-12-18 E.I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US20120213713A1 (en) * 2011-02-18 2012-08-23 Chifu Huang Compositions of omega fatty acids for the prevention and treatment of dental caries resulting from oral infections
US8703818B2 (en) 2011-03-03 2014-04-22 Tersus Pharmaceuticals, LLC Compositions and methods comprising C16:1n7-palmitoleate
US8569530B2 (en) * 2011-04-01 2013-10-29 Aurora Algae, Inc. Conversion of saponifiable lipids into fatty esters
EP2734626B1 (en) * 2011-07-21 2020-12-16 DSM IP Assets B.V. Microbial oils enriched in polyunsaturated fatty acids
WO2013075116A2 (en) 2011-11-17 2013-05-23 Heliae Development, Llc Omega 7 rich compositions and methods of isolating omega 7 fatty acids
US20140275483A1 (en) 2013-03-15 2014-09-18 Aurora Algae, Inc. Algal oil compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091524A1 (en) * 2001-03-22 2004-05-13 Nobukazu Tanaka Stable astaxanthin-containing powdery compositions and process for producing the same
US20100069492A1 (en) * 2006-07-05 2010-03-18 Photonz Corporation Limited Production of ultrapure epa and polar lipids from largely heterotrophic culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRIENITZ, L ET AL.: "The high content of polyunsaturated fatty acids in Nannochloropsis limnetica (Eustigmatophyceae) and its implication for food web interactions, freshwater aquaculture and biotechnology';", LIMNOLOGICA;, vol. 36, 29 September 2006 (2006-09-29), pages 204 - 210, XP028020576, Retrieved from the Internet <URL:http://www.sciencedirect.com/ science /article/pii/S0075951106000363> [retrieved on 20140623] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445619B2 (en) 2013-03-15 2016-09-20 Aurora Algae, Inc. Compositions and methods for utilization of algal compounds

Also Published As

Publication number Publication date
WO2014151116A1 (en) 2014-09-25
CA2905846A1 (en) 2014-09-25
US20140273113A1 (en) 2014-09-18
AU2014232150A1 (en) 2015-08-20
EP2968244A1 (en) 2016-01-20
WO2014151113A1 (en) 2014-09-25
HK1220683A1 (en) 2017-05-12
CN105209034A (en) 2015-12-30
CA2906532A1 (en) 2014-09-25
US20140275613A1 (en) 2014-09-18
CN105121623A (en) 2015-12-02
EP2968244A4 (en) 2016-10-26
US20140275483A1 (en) 2014-09-18
CN105102598A (en) 2015-11-25
EP2970817A1 (en) 2016-01-20
US9445619B2 (en) 2016-09-20
US20140274922A1 (en) 2014-09-18
US20140275596A1 (en) 2014-09-18
IL240339A0 (en) 2015-09-24
WO2014146133A2 (en) 2014-09-18
US20140271706A1 (en) 2014-09-18
MX2015012321A (en) 2015-12-16
CN105263896A (en) 2016-01-20
WO2014146133A3 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
US20140275483A1 (en) Algal oil compositions
Béligon et al. Microbial lipids as potential source to food supplements
US20200078464A1 (en) Polyunsaturated fatty acid-containing solid fat compositions and uses and production thereof
Mišurcová et al. Seaweed lipids as nutraceuticals
US20040209953A1 (en) Glyceride compositions and methods of making and using same
Robertson et al. Algae-derived polyunsaturated fatty acids: implications for human health
US10314871B2 (en) Isolation of Omega-7 fatty acid ethyl esters from natural oils
Ratledge Microbial production of polyunsaturated fatty acids as nutraceuticals
Patel et al. Introduction to essential fatty acids
WO2017038860A1 (en) Free polyunsaturated fatty acid-containing composition and manufacturing method therefor
Bilgiç et al. Lipase‐catalyzed acidolysis of olive oil with echium oil stearidonic acid: optimization by response surface methodology
Rincón-Cervera et al. Monounsaturated and polyunsaturated fatty acids: structure, food sources, biological functions, and their preventive role against noncommunicable diseases
JP2022500049A (en) Extraction method of oil rich in polyunsaturated fatty acid (PUFA)
Dhull et al. Sources: plants, animals and microbial
De et al. Characterization of lipids and fatty acids of the soil derived fungus Cladosporium sp.
Matos Essential fatty acids from microalgae
Ferreri Omega 3 fatty acids and bioactive foods: from biotechnology to health promotion
Paul et al. Functional and Bioactive Lipid Mediators in Modulating CVD Precursors
Mensah Food Bioactive Compounds–Polyunsaturated Fatty Acids (PUFA): Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Habeeb et al. An overview of lipids from plant sources
Singh et al. 3 BiotechnologicalofAlgaein Pharmaceuticals Application Industries with Special Reference to Omega-3 Fatty Acid and Human Health
Ouyang et al. Resources and bioactivities of polyunsaturated fatty acids
Punia et al. Omega 3-Metabolism, Absorption, Bioavailability and
WO2011143229A2 (en) Lipid compositions and structured lipids containing phospholipids, oral formulations containing the same and methods of making the same
RU2018122617A (en) DHA-Enriched Polyunsaturated Fatty Acid Compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480015962.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14769076

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2905846

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014769076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014769076

Country of ref document: EP